Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

841 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children.
Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Kigasawa H, Kosaka Y, Miyachi H, Horibe K, Nakahata T, Adachi S. Tomizawa D, et al. Among authors: kinoshita a. Leukemia. 2013 Dec;27(12):2413-6. doi: 10.1038/leu.2013.153. Epub 2013 May 16. Leukemia. 2013. PMID: 23677335 No abstract available.
Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Kiyokawa N, Isoyama K, Mizutani S, Hara J, Horibe K, Nakahata T, Adachi S. Tomizawa D, et al. Among authors: kinoshita a. Int J Hematol. 2013 Nov;98(5):578-88. doi: 10.1007/s12185-013-1429-2. Epub 2013 Sep 26. Int J Hematol. 2013. PMID: 24068655 Free PMC article.
Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
Hasegawa D, Tawa A, Tomizawa D, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Miyachi H, Horibe K, Nakahata T, Adachi S. Hasegawa D, et al. Among authors: kinoshita a. Pediatr Blood Cancer. 2020 Dec;67(12):e28692. doi: 10.1002/pbc.28692. Epub 2020 Sep 4. Pediatr Blood Cancer. 2020. PMID: 32886449
Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial.
Tokumasu M, Murata C, Shimada A, Ohki K, Hayashi Y, Saito AM, Fujimoto J, Horibe K, Nagao M, Itoh H, Kamikubo Y, Nakayama H, Kinoshita A, Tomizawa D, Taga T, Tawa A, Tanaka S, Heike T, Adachi S. Tokumasu M, et al. Among authors: kinoshita a. Leukemia. 2015 Dec;29(12):2438-41. doi: 10.1038/leu.2015.121. Epub 2015 May 15. Leukemia. 2015. PMID: 25975190 No abstract available.
Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M; Tokyo Children's Cancer Study Group. Tomizawa D, et al. Among authors: kinoshita a. Pediatr Blood Cancer. 2007 Aug;49(2):127-32. doi: 10.1002/pbc.20944. Pediatr Blood Cancer. 2007. PMID: 16807916 Clinical Trial.
EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Shiba N, Ohki K, Hayashi Y, Yamashita Y, Shimada A, Tanaka S, Adachi S. Matsuo H, et al. Among authors: kinoshita a. Haematologica. 2014 Nov;99(11):e225-7. doi: 10.3324/haematol.2014.107128. Epub 2014 Jul 11. Haematologica. 2014. PMID: 25015941 Free PMC article. No abstract available.
Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols.
Tomizawa D, Watanabe T, Hanada R, Horibe K, Horikoshi Y, Iwamoto S, Kinoshita A, Moritake H, Nakayama H, Shimada A, Taga T, Takahashi H, Tawa A, Terui K, Hori H, Kawano Y, Kikuta A, Manabe A, Adachi S. Tomizawa D, et al. Among authors: kinoshita a. Int J Hematol. 2015 Sep;102(3):318-26. doi: 10.1007/s12185-015-1825-x. Epub 2015 Jul 1. Int J Hematol. 2015. PMID: 26126642 Clinical Trial.
Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.
Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H, Kinoshita A, Iwamoto S, Nakayama H, Takahashi H, Shimada A, Taki T, Toki T, Ito E, Goto H, Koh K, Saito AM, Horibe K, Nakahata T, Tawa A, Adachi S. Taga T, et al. Among authors: kinoshita a. Pediatr Blood Cancer. 2016 Feb;63(2):248-54. doi: 10.1002/pbc.25789. Epub 2015 Oct 20. Pediatr Blood Cancer. 2016. PMID: 26481183 Clinical Trial.
841 results